Page 1592 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 86 Plasma Cell Neoplasms 1418.e1

REFERENCES 23. Shaughnessy JD, Jr, Zhan F, Burington BE, et al: A validated gene
expression model of high-risk multiple myeloma is defined by deregulated
1. Landgren O, Kyle RA, Pfeiffer RM, et al: Monoclonal gammopathy expression of genes mapping to chromosome 1. Blood 109:2276–2284,
of undetermined significance (MGUS) consistently precedes multiple 2007.
myeloma: a prospective study. Blood 113:5412–5417, 2009. 24. Decaux O, Lode L, Magrangeas F, et al: Prediction of survival in multiple
2. Sawyer JR: The prognostic significance of cytogenetics and molecular myeloma based on gene expression profiles reveals cell cycle and chro-
profiling in multiple myeloma. Cancer Genet 204:3–12, 2011. mosomal instability signatures in high-risk patients and hyperdiploid
3. Avet-Loiseau H, Attal M, Campion L, et al: Long-term analysis of the signatures in low-risk patients: a study of the Intergroupe Francophone
IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), du Myélome. J Clin Oncol 26:4798–4805, 2008.
1q gains] play a major role in defining long-term survival. J Clin Oncol 25. Kyle RA, Remstein ED, Therneau TM, et al: Clinical course and prog-
30:2012, 1949. nosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med
4. Avet-Loiseau H, Minvielle S, Mellerin MP, et al: 14q32 chromosomal 356:2582–2590, 2007.
translocations: a hallmark of plasma cell dyscrasias? Hematol J 1:292, 26. Kyle RA, Therneau TM, Rajkumar SV, et al: A long-term study of
2000. prognosis in monoclonal gammopathy of undetermined significance. N
5. Broyl A, Hose D, Lokhorst H, et al: Gene expression profiling for Engl J Med 346:564–569, 2002.
molecular classification of multiple myeloma in newly diagnosed 27. Harousseau JL, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexa-
patients. Blood 116:2543–2553, 2010. methasone is superior to vincristine plus doxorubicin plus dexamethasone
6. Avet-Loiseau H, Li C, Magrangeas F, et al: Prognostic significance of as induction treatment prior to autologous stem-cell transplantation in
copy-number alterations in multiple myeloma. J Clin Oncol 27:4585– newly diagnosed multiple myeloma: results of the IFM 2005-01 phase
4590, 2009. III trial. J Clin Oncol 28:4621–4629, 2010.
7. Carrasco DR, Tonon G, Huang Y, et al: High-resolution genomic pro- 28. Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and
files define distinct clinico-pathogenetic subgroups of multiple myeloma dexamethasone combination therapy in patients with newly diagnosed
patients. Cancer Cell 9:313–325, 2006. multiple myeloma. Blood 116:679–686, 2010.
8. Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, et al: Deregula- 29. Kumar S, Flinn I, Richardson PG, et al: Randomized, multicenter,
tion of microRNA expression in the different genetic subtypes of mul- phase 2 study (EVOLUTION) of combinations of bortezomib, dexa-
tiple myeloma and correlation with gene expression profiling. Leukemia methasone, cyclophosphamide, and lenalidomide in previously untreated
24:629–637, 2010. multiple myeloma. Blood 119:4375, 2012.
9. Salhia B, Baker A, Ahmann G, et al: DNA methylation analysis 30. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized
determines the high frequency of genic hypomethylation and low trial of autologous bone marrow transplantation and chemotherapy in
frequency of hypermethylation events in plasma cell tumors. Cancer Res multiple myeloma. Intergroupe Francophone du Myélome. N Engl J Med
70:6934–6944, 2010. 335:91–97, 1996.
10. Hideshima T, Mitsiades C, Tonon G, et al: Understanding multiple 31. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with
myeloma pathogenesis in the bone marrow to identify new therapeutic hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med
targets. Nat Rev Cancer 7:585–598, 2007. 348:1875–1883, 2003.
11. Raje N, Roodman GD: Advances in the biology and treatment of bone 32. Koreth J, Cutler CS, Djulbegovic B, et al: High-dose therapy with single
disease in multiple myeloma. Clin Cancer Res 17:1278–1286, 2011. autologous transplantation versus chemotherapy for newly diagnosed
12. Braga WM, Atanackovic D, Colleoni GW: The role of regulatory T cells multiple myeloma: a systematic review and meta-analysis of randomized
and TH17 cells in multiple myeloma. Clin Dev Immunol 293479:2012, controlled trials. Biol Blood Marrow Transplant 13:183, 2007.
2012. 33. Attal M, Harousseau JL, Facon T, et al: Single versus double autolo-
13. Prabhala RH, Pelluru D, Fulciniti M, et al: Elevated IL-17 produced gous stem-cell transplantation for multiple myeloma. N Engl J Med
by TH17 cells promotes myeloma cell growth and inhibits immune 349:2495–2502, 2003.
function in multiple myeloma. Blood 115:5385–5392, 2010. 34. Cavo M, Pantani L, Petrucci MT, et al: Bortezomib-thalidomide-
14. Joshua DE: Biology of multiple myeloma—host–tumour interactions dexamethasone is superior to thalidomide-dexamethasone as consolida-
and immune regulation of disease activity. Hematol Oncol 6:83, 1988. tion therapy after autologous hematopoietic stem cell transplantation in
15. Tian E, Zhan F, Walker R, et al: The role of the Wnt-signaling antagonist patients with newly diagnosed multiple myeloma. Blood 120:9, 2012.
DKK1 in the development of osteolytic lesions in multiple myeloma. N 35. Bruno B, Rotta M, Patriarca F, et al: A comparison of allografting with
Engl J Med 349:2483, 2003. autografting for newly diagnosed myeloma. N Engl J Med 356:1110–
16. Hutchison CA, Batuman V, Behrens J, et al: The pathogenesis and 1120, 2007.
diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 36. Reece DE: Posttransplantation maintenance therapy and optimal front-
8:43–51, 2012. line therapy in myeloma. Hematology Am Soc Hematol Educ Program
17. Ludwig H, Pohl G, Osterborg A: Anemia in multiple myeloma. Clin 2011:197, 2011.
Adv Hematol Oncol 2:233, 2004. 37. Lonial S, Mitsiades CS, Richardson PG: Treatment options for relapsed
18. Nucci M, Anaissie E: Infections in patients with multiple myeloma in the and refractory multiple myeloma. Clin Cancer Res 17:1264–1277, 2011.
era of high-dose therapy and novel agents. Clin Infect Dis 49:1211–1225, 38. Moreau P, Pylypenko H, Grosicki S, et al: Subcutaneous versus intra-
2009. venous administration of bortezomib in patients with relapsed multiple
19. Dimopoulos M, Kyle R, Fermand JP, et al: Consensus recommendations myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol
for standard investigative workup: report of the International Myeloma 12:431–440, 2011.
Workshop Consensus Panel 3. Blood 117:4701–4705, 2011. 39. Morgan GJ, Child JA, Gregory WM, et al: Effects of zoledronic acid
20. International Myeloma Working Group: Criteria for the classification versus clodronic acid on skeletal morbidity in patients with newly
of monoclonal gammopathies, multiple myeloma and related disorders: diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes
a report of the International Myeloma Working Group. Br J Haematol from a randomised controlled trial. Lancet Oncol 12:743–752, 2011.
121:749, 2003. 40. Morgan GJ, Davies FE, Gregory WM, et al: First-line treatment with
21. Munshi NC, Anderson KC, Bergsagel PL, et al: Consensus recommen- zoledronic acid as compared with clodronic acid in multiple myeloma
dations for risk stratification in multiple myeloma: report of the Inter- (MRC Myeloma IX): a randomised controlled trial. Lancet 376:1989–
national Myeloma Workshop Consensus Panel 2. Blood 117:4696–4700, 1999, 2010.
2011. 41. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melpha-
22. Greipp PR, San Miguel J, Durie BG, et al: International staging system lan and prednisone for initial treatment of multiple myeloma. N Engl J
for multiple myeloma. J Clin Oncol 23:3412–3420, 2005. Med 359:906–917, 2008.